Roche’s Actemra helps rheumatoid arthritis

	Tweet

Roche said on Thursday its Actemra drug, developed by Japanese partner Chugai, was better than current standard treatments in preventing the progression of joint destruction in patients with rheumatoid arthritis.

According to late-stage clinical trial data presented at a meeting in San Diego, the drug when used alone was superior to conventional drugs, known as DMARDs, in inhibiting the spread of joint destruction.

The data also showed that Actemra dramatically improved the painful and disabling symptoms of patients with rheumatoid arthritis.

Actemra is one of two drugs Roche hopes will give it a foothold in the market for treating rheumatoid arthritis (RA), a debilitating autoimmune disease in which the lining of joints becomes inflamed causing joint damage and destruction. 

RELATED STORIES:
Arthritis Common in Children   NSAID gel curbs pain of knee arthritis   Another use for statins - treating rheumatoid arthritis   Rheumatoid Arthritis Patients Have Low Expectations After Knee Replacement Surgery   Arthritis drug appears safe for liver   Vitamin C rich diet may cut arthritis risk   Aerobic exercise safe and effective for rheumatoid arthritis patients   Abbott adds warnings to arthritis drug label   Leflunomide effective as co-therapy in RA   New Surgical Option for Wrist Arthritis   Exercise programs recommended as standard for rheumatoid arthritis   Statins may increase arthritis risk in elderly women

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]